Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy

According to the analysis on locally advanced breast cancer (LABC) from all breast cancer cases recorded in Surveillance Epidemiology and End Results database between the years 1992 - 1999 in the United States, the incidence of LABC were found to be 4,6 % of all female breast cancers. Clinically, wh...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2013
Автор: Yalcin, B.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2013
Назва видання:Experimental Oncology
Теми:
Онлайн доступ:http://dspace.nbuv.gov.ua/handle/123456789/145234
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy / B. Yalcin // Experimental Oncology. — 2013. — Т. 35, № 4. — С. 250-252. — Бібліогр.: 23 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id irk-123456789-145234
record_format dspace
spelling irk-123456789-1452342019-01-20T01:23:26Z Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy Yalcin, B. Special issue on breast cancer According to the analysis on locally advanced breast cancer (LABC) from all breast cancer cases recorded in Surveillance Epidemiology and End Results database between the years 1992 - 1999 in the United States, the incidence of LABC were found to be 4,6 % of all female breast cancers. Clinically, when breast cancer has advanced locoregionally but has not yet spread outside of the breast and regional lymph nodes, it is considered LABC. LABC includes breast cancers that have evidence of a large mass, involve the skin of the breast or the underlying muscles of the chest wall, and cancers that have infiltrated into the local lymph nodes. The prognosis of patients with LABC is relatively poor, with 5-year survival rates less than 50 %. Because the incidence of LABC is very low, there are not many studies comparing neoadjuvant chemotherapy regimens in the literature. In management of LABC, initial therapy should be systemic neoadjuvant chemotherapy, aiming pCR. Anthracycline-based chemotherapy regimens are frequently recommended as the standard primary neoadjuvant chemotherapy for the treatment of LABC. Today the optimal duration of neoadjuvant chemotherapy is unknown. Neoadjuvant endocrine therapy is considered an option for patients with honnone receptor-positive LABC. Ongoing clinical trials are now under way to evaluate the use of novel targeted agents in the neoadjuvant treatment of LABC. 2013 Article Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy / B. Yalcin // Experimental Oncology. — 2013. — Т. 35, № 4. — С. 250-252. — Бібліогр.: 23 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/145234 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Special issue on breast cancer
Special issue on breast cancer
spellingShingle Special issue on breast cancer
Special issue on breast cancer
Yalcin, B.
Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy
Experimental Oncology
description According to the analysis on locally advanced breast cancer (LABC) from all breast cancer cases recorded in Surveillance Epidemiology and End Results database between the years 1992 - 1999 in the United States, the incidence of LABC were found to be 4,6 % of all female breast cancers. Clinically, when breast cancer has advanced locoregionally but has not yet spread outside of the breast and regional lymph nodes, it is considered LABC. LABC includes breast cancers that have evidence of a large mass, involve the skin of the breast or the underlying muscles of the chest wall, and cancers that have infiltrated into the local lymph nodes. The prognosis of patients with LABC is relatively poor, with 5-year survival rates less than 50 %. Because the incidence of LABC is very low, there are not many studies comparing neoadjuvant chemotherapy regimens in the literature. In management of LABC, initial therapy should be systemic neoadjuvant chemotherapy, aiming pCR. Anthracycline-based chemotherapy regimens are frequently recommended as the standard primary neoadjuvant chemotherapy for the treatment of LABC. Today the optimal duration of neoadjuvant chemotherapy is unknown. Neoadjuvant endocrine therapy is considered an option for patients with honnone receptor-positive LABC. Ongoing clinical trials are now under way to evaluate the use of novel targeted agents in the neoadjuvant treatment of LABC.
format Article
author Yalcin, B.
author_facet Yalcin, B.
author_sort Yalcin, B.
title Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy
title_short Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy
title_full Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy
title_fullStr Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy
title_full_unstemmed Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy
title_sort overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2013
topic_facet Special issue on breast cancer
url http://dspace.nbuv.gov.ua/handle/123456789/145234
citation_txt Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy / B. Yalcin // Experimental Oncology. — 2013. — Т. 35, № 4. — С. 250-252. — Бібліогр.: 23 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT yalcinb overviewonlocallyadvancedbreastcancerdefiningepidemiologyandoverviewonneoadjuvanttherapy
first_indexed 2023-05-20T17:21:36Z
last_indexed 2023-05-20T17:21:36Z
_version_ 1796153117402726400